Emergent Biosolutions ((EBS)) announced an update on their ongoing clinical study.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Study Overview: Emergent BioSolutions is conducting a study titled ‘Pharmacokinetics of Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) – (Equine) (BAT®) in Pediatric Patients With a Confirmed or Suspected Exposure to Botulinum Neurotoxin.’ The study aims to verify pediatric dosing recommendations for the BAT product in children exposed to botulinum neurotoxin, ensuring safety and efficacy.
Intervention/Treatment: The intervention involves collecting one to three blood samples from pediatric patients treated with the BAT product. This biological intervention aims to monitor the pharmacokinetics of the antitoxin in the pediatric population.
Study Design: This is an interventional Phase 4 study with a single-group model and no masking. The primary purpose is basic science, focusing on understanding the pharmacokinetics of the BAT product in children.
Study Timeline: The study began on January 29, 2014, and is currently enrolling participants by invitation. The latest update was submitted on August 18, 2025, indicating ongoing progress and data collection.
Market Implications: The study’s progress could positively impact Emergent BioSolutions’ stock performance by reinforcing investor confidence in the company’s commitment to safety and efficacy in pediatric treatments. The successful completion of this study may position Emergent favorably against competitors in the biopharmaceutical industry, particularly in the niche market of botulism treatment.
The study is ongoing, with further details available on the ClinicalTrials portal.